Auto-generated from public data. Not the firm's stated position.
Pureos Bioventures appears to focus on early to growth-stage biotech investments, with a disclosed portfolio concentrated in specialized therapeutic areas including oncology, antifibrosis, and antibody-drug conjugate technologies. Based on disclosed data, the firm operates from Switzerland and deploys check sizes starting at approximately €3.0M across series-A through growth-stage rounds.
Generated 19 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Auto-detected from Pureos Bioventures's website.
Joined Pureos in 2021, former Analyst fellow at M Ventures, Post-Doc at University of Basel.
Joined Pureos in 2023, led antiviral drug development at University of Basel, collaborated on rare neurological therapies.
Founding partner of Pureos, co-founder and Executive Chairman of CDR-Life, former founder and CEO of ESBATech acquired by Alcon for $589M.
CSO and co-founder of Covagen AG acquired by Cilag/J&J in 2014, independent advisor and start-up coach.
Founding partner of Pureos, venture capital investor since 2001 across multiple regions, stages and company types.
CEO of Engimmune Therapeutics, 20+ years leadership in pharmaceutical product development and innovative technologies.
Founding partner of Pureos, venture capital investor since 1999 in life science companies across all stages and types.
Founder CEO of GlycoEra, co-founder and CEO of LimmaTech Biologics, executive at GlycoVaxyn acquired by GSK in 2015.
Professor at ETH Zurich, co-founder of deepCDR Biologics and Engimmune Therapeutics, expert in systems and synthetic immunology.
Focus and check size from the firm's website. Website reachable as of Aug 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.